ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Monday, August 8, 2022
At the Board meeting of the Company held on Monday, August 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 8, 2022 are enclosed herewith. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 8, 2022
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Monday, August 8, 2022 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from June 16, 2022 to August 10, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated July 4, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements of Intimation of 43rd Annual General Meeting & e-voting ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1010 Name of the Signatory :- Pratap Rudra Designation :- Company Secretary and Compliance Officer ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Reg. 34 (1) Annual Report.
Pursuant to Regulation 34(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the Company for the financial year ended March 31, 2022 along with the Notice of the Annual General Meeting of the Company scheduled to be held on Monday, August 8, 2022 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Annual Report is being sent to the members who have registered their email ID with the Company/ Depositories. The Annual Report is also available on the website of the Company at www.astrazeneca.com/india. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Notice Of 43Rd Annual General Meeting
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 43rd Annual General Meeting of the Company scheduled to be held on Monday, August 8, 2022 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent to the members of the Company through electronic mode. The said Notice and the Annual Report for the financial year ended March 31, 2022 is available on the website of the Company at www.astrazeneca.com/india. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Communication To The Shareholders W.R.T. TDS On Final Dividend
Pursuant to the recommendation of the Final Dividend by the Board of Directors of the Company at its meeting held on May 26, 2022, the Company has sent the enclosed e-mail communication to its shareholders, with respect to the deduction of tax at source on Final Dividend for the financial year 2021-22, whose email addresses are registered with the Company/ Depository Participants. The specimen of the communication is appended herewith for your reference and records, and the same will also be available on the website of the Company at www.astrazeneca.com/india. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Increase In Volume
This has reference to your email dated July 6, 2022 bearing reference no. L/SURV/ONL/PV/NP/ 2022-2023 / 98 on the captioned subject. We wish to inform you that we have no information/announcement including pending announcement which in the Company's opinion may have a bearing on the price/volume behavior in the scrip. We thank you for drawing our attention and assure you of Company's continued adherence to its obligation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.